Evidence map›Paper›PMID 32859615›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2020

Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.

Justin C Brown, Sui Zhang, Jennifer A Ligibel, Melinda L Irwin, Lee W Jones, Nancy Campbell, Michael N Pollak, Alexandra Sorrentino, Brenda Cartmel, Maura Harrigan and 9 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Justin C BrownPennington Biomedical Research Center, Baton Rouge, Louisiana. justin.brown@pbrc.edu.ORCID 0000-0001-7540-4913
Sui ZhangDana-Farber Cancer Institute, Boston, Massachusetts.
Jennifer A LigibelDana-Farber Cancer Institute, Boston, Massachusetts.
Melinda L IrwinYale University, New Haven, Connecticut.
Lee W JonesMemorial Sloan Kettering Cancer Center, New York, New York.
Nancy CampbellDana-Farber Cancer Institute, Boston, Massachusetts.
Michael N PollakMcGill University, Jewish General Hospital, Montreal, Quebec, Canada.
Alexandra SorrentinoDana-Farber Cancer Institute, Boston, Massachusetts.
Brenda CartmelYale University, New Haven, Connecticut.
Maura HarriganYale University, New Haven, Connecticut.
Sara M TolaneyDana-Farber Cancer Institute, Boston, Massachusetts.
Eric P WinerDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-8819-1723
Kimmie NgDana-Farber Cancer Institute, Boston, Massachusetts.
Thomas A AbramsDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-3101-1573
Tara SanftYale University, New Haven, Connecticut.
Pamela S DouglasDuke University, Durham, North Carolina.
Frank B HuHarvard School of Public Health, Boston, Massachusetts.
Charles S FuchsYale University, New Haven, Connecticut.
Jeffrey A MeyerhardtDana-Farber Cancer Institute, Boston, Massachusetts.
Dana-Farber Cancer Institute · USYale University · USDuke University · USHarvard University · USJewish General Hospital · CAMemorial Sloan Kettering Cancer Center · USPennington Biomedical Research Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Research BaseP30DK072476 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Sujoy Ghosh · 2005 to 2026
$26.5M
Sleep Duration, Childhood Energy Balance, and Insulin Resistance in AdolescenceU54CA155626 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI STAMPFER, MEIR · 2011 to 2015
$9.6M
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biologyR01CA205406 · NCI · DANA-FARBER CANCER INST · PI Kimmie Ng · 2017 to 2026
$4.9M
Dietary And Lifestyle Determinants Of Colon Cancer Recurrence and SurvivalR01CA118553 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2007 to 2019
$4.4M
Impact of Celecoxib and Inflammation on Survival in Stage III Colon CancerR01CA169141 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2013 to 2018
$3.9M
Transdisciplinary Research in Energetics and Cancer (TREC) Training GrantR25CA203650 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L · 2016 to 2025
$2.9M
Inflammation, Physical Activity, and Colon Cancer Recurrence and SurvivalR00CA218603 · NCI · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI BROWN, JUSTIN C · 2019 to 2021
$747k
Inflammation, Physical Activity, and Colon Cancer Recurrence and SurvivalK99CA218603 · NCI · DANA-FARBER CANCER INST · PI BROWN, JUSTIN C · 2017 to 2018
$260k
NCI NIH HHS K99 CA218603NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA218603NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA169141NCI NIH HHS R01 CA205406NCI NIH HHS R25 CA203650NCI NIH HHS U54 CA155626NIDDK NIH HHS P30 DK072476NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

Observational studies report that physical activity and metformin are associated with improved clinical outcome in patients with cancer. Inflammation is one biological mechanism hypothesized to mediate these associations. In this phase II, multicenter, 2 × 2 factorial trial, 139 patients with breast and colorectal cancer who completed standard therapy were randomized to one of four treatment groups for 12 weeks: exercise alone, metformin alone, exercise and metformin, or control. Inflammation outcomes included high-sensitivity C-reactive protein (hs-CRP), soluble tumor necrosis factor alpha receptor two (sTNFαR2), and IL6. The primary modeling strategy evaluated the trial product estimand that was quantified using a generalized linear mixed model. Compared with control, exercise alone reduced hs-CRP [-30.2%; 95% confidence interval (CI), -50.3, -1.0] and IL6 (-30.9%; 95% CI, -47.3, -9.5) but did not change sTNFαR2 (1.0%; 95% CI, -10.4, 13.9). Compared with control, metformin alone did not change hs-CRP (-13.9%; 95% CI, -40.0, 23.4), sTNFαR2 (-10.4%; 95% CI, -21.3, 2.0), or IL6 (-22.9%; 95% CI, -42.3, 2.0). Compared with control, exercise and metformin reduced sTNFαR2 (-13.1%; 95% CI, -22.9, -1.0) and IL6 (-38.7%; 95% CI, -52.3, -18.9) but did not change hs-CRP (-20.5%; 95% CI, -44.0, 12.7). The combination of exercise and metformin was not synergistic for hs-CRP, sTNFαR2, or IL6. In survivors of breast and colorectal cancer with low baseline physical activity and without type 2 diabetes, exercise and metformin reduced measures of inflammation that are associated with cancer recurrence and mortality.

Indexed as

BiomarkersBreast NeoplasmsColorectal NeoplasmsCombined Modality TherapyC-Reactive ProteinExercise TherapyFemaleFollow-Up StudiesHumansHypoglycemic AgentsInflammationMaleMetforminMiddle AgedPrognosisUnited StatesBiomarkersC-Reactive ProteinHypoglycemic AgentsMetformin

Identifiers

PMID32859615
PMCPMC7718298
OpenAlexW3081755459

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.